The importance of drug discovery for treatment of cardiovascular diseases

作者: Charles Kennedy

DOI: 10.4155/FMC.13.20

关键词:

摘要: Cardiovascular disease is the main cause of death across world, accounting for approximately one third all fatalities annually. This equates to 17 million people dying each year from coronary heart and stroke in particular, as well peripheral arterial aortic [101]. In UK combined lead 131,000 deaths per year, or, on average, every 4 min [102,103]. Furthermore, projections indicate that cardiovascular will kill nearly 25 globally by 2030, maintaining its position leading death. addition morbidity, impacts upon quality life an even greater number people. For example, more than 1 women 1.6 men have [103], which can leave them feeling ill, tired short breath, which, turn, greatly limits their ability carry out everyday activities live a full, normal life.

参考文章(16)
Pedro L Zamora, Frederick A Villamena, Pharmacological approaches to the treatment of oxidative stress-induced cardiovascular dysfunctions Future Medicinal Chemistry. ,vol. 5, pp. 465- 478 ,(2013) , 10.4155/FMC.13.15
Jens Minnerup, Christoph Kleinschnitz, No risk, no benefit: still true for antithrombotic stroke treatments? Future Medicinal Chemistry. ,vol. 5, pp. 377- 379 ,(2013) , 10.4155/FMC.12.214
Alessandra Ghigo, Fulvio Morello, Alessia Perino, Emilio Hirsch, Therapeutic applications of PI3K inhibitors in cardiovascular diseases. Future Medicinal Chemistry. ,vol. 5, pp. 479- 492 ,(2013) , 10.4155/FMC.13.11
Virgilio JJ Cadete, Steven A Arcand, Han-Bin Lin, Grzegorz Sawicki, Synergistic protection of MLC 1 against cardiac ischemia/reperfusion-induced degradation: a novel therapeutic concept for the future Future Medicinal Chemistry. ,vol. 5, pp. 389- 398 ,(2013) , 10.4155/FMC.13.19
Louisa CY Lee, Donald H Maurice, George S Baillie, Targeting protein-protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease. Future Medicinal Chemistry. ,vol. 5, pp. 451- 464 ,(2013) , 10.4155/FMC.12.216
Naama Zeevi-Levin, Joseph Itskovitz-Eldor, Ofer Binah, Functional cardiomyocytes from human stem cells: a tool for determining the cardiotoxic potential of preclinical drugs Future Medicinal Chemistry. ,vol. 5, pp. 363- 366 ,(2013) , 10.4155/FMC.13.22
Atul Bhardwaj, Jatinder Kaur, Edward E Knaus, Can nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks? Future Medicinal Chemistry. ,vol. 5, pp. 381- 383 ,(2013) , 10.4155/FMC.13.23
Sven Ruf, Christian Buning, Herman Schreuder, Wolfgang Linz, Thomas Hübschle, Dominik Linz, Hartmut Ruetten, Klaus Wirth, Thorsten Sadowski, Inhibition of CatA: an emerging strategy for the treatment of heart failure Future Medicinal Chemistry. ,vol. 5, pp. 399- 409 ,(2013) , 10.4155/FMC.13.24
Charles Kennedy, Krongkarn Chootip, Callum Mitchell, Nawazish-i-Husain Syed, Asrin Tengah, None, P2X and P2Y nucleotide receptors as targets in cardiovascular disease Future Medicinal Chemistry. ,vol. 5, pp. 431- 439 ,(2013) , 10.4155/FMC.13.6